All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley Freilich, Ziad Younes, William R. Harlan, Reem Ghalib, Godson Oguchi, Paul J. Thuluvath, Grisell Ortiz‐Lasanta, Mordechai Rabinovitz, David Bernstein, Michael Bennett, Trevor Hawkins, Natarajan Ravendhran, Aasim Sheikh, Peter Varunok, Kris V. Kowdley, Delphine Hennicken, Fiona McPhee, Khurram Rana, Eric Hughes, on behalf of the ALLY‐3 Study Team

Hepatology, 2015

University of Florida, Inova Fairfax Hospital, Quest Clinical Research (United States), The University of Texas Health Science Center at San Antonio, Texas Liver Institute, Scripps Clinic, Atlanta Gastroenterology Associates, Kansas City Research Institute, Gastro One (United States), Asheville Cardiology Associates, Clinical Research Institute, Meridien Research, Orlando Clinical Research Center, Mercy Medical Center, Puerto Rico Community Foundation, University of Pittsburgh, Medical Research Associates, Southwest Regional Wound Care Center, Digestive Care (United States), GI Specialists of Georgia (United States), Virginia Mason Medical Center, Bristol-Myers Squibb (Belgium), Bristol-Myers Squibb (United States)

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with Hepatology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

688

Citations

View on Google Scholar

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

Abstract

Journal Details

Join JournalsHub

Welcome Back